IR News 2020

(Media)Nippon Shinyaku Submitted Additional Application of Uptravi for "Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”

(Media)The "Moshikashite NMD" project is launched. Special dance and check tools are developed collaboratively to help discover neuromuscular disorders earlier.

Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2020

VILTEPSO (viltolarsen) injection Now Commercially Available in the U.S.

VILTEPSO (viltolarsen) Now Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2020

(Media)Investment in the Newly Established Biotech Funds

(Media)EC Grants Orphan Drug Designation to viltolarsen (NS-065/NCNP-01)

(Media)MHLW approval of ERLEADA® (apalutamide) for the Treatment of Patients with Prostate Cancer with Distant Metastases

(Media)Launch of VILTEPSO® (viltolarsen) Intravenous Infusion 250 mg for the treatment of Duchenne muscular dystrophy patients amenable to exon 53 skipping therapy in Japan

Outline of Consolidated Financial Results for the Year Ended March 31, 2020

First Patient Enrolled in Phase 3 Trial of Viltolarsen (NS-065/NCNP-01), an Investigational Antisense Oligonucleotide

(Media)Notification of MA Transfer Completion of Tadalafil Products

(Media)Marketing authorization in Japan of VILTEPSO® Intravenous Infusion 250 mg for the treatment of Duchenne muscular dystrophy

(Media)NDA Accepted for Filing by the FDA for Antisense Oligonucleotide Viltolarsen (NS-065/NCNP-01)

(Media)Nippon Shinyaku signs a new co-promotion agreement with Janssen Pharmaceutical K.K. for ZYTIGA® in Japan

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2019